The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
Open accessAbstract
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with virologic failure at Week 48 were evaluated post hoc. Design and methods: Data from 1039 adults naive to long-acting CAB+RPV were pooled in a multivariable analysis to examine the influence of baseline viral and participant factors, dosing regimen and drug concentrations on confirmed virologic failure (CVF) occurrence using a logistic regression model. In a separate model, baseline factors statistically associated with CVF were further evaluated to understand CVF risk when present alone or in combination. Results: Overall, 1.25% (n = 13/1039) of participants experienced CVF. Proviral RPV resistance-associated mutations (RAMs), HIV-1 subtype A6/A1, higher BMI (associated with Week 8 CAB trough concentration) and lower Week 8 RPV trough concentrations were significantly associated (P < 0.05) with increased odds of CVF (all except RPV trough are knowable at baseline). Few participants (0.4%) with zero or one baseline factor had CVF. Only a combination of at least two baseline factors (observed in 3.4%; n = 35/1039) was associated with increased CVF risk (25.7%, n = 9/35). Conclusion: CVF is an infrequent multifactorial event, with a rate of approximately 1% in the long-acting CAB+RPV arms across Phase 3 studies (FLAIR, ATLAS and ATLAS-2M) through Week 48. Presence of at least two of proviral RPV RAMs, HIV-1 subtype A6/A1 and/or BMI at least 30 kg/m 2 was associated with increased CVF risk. These findings support the use of long-acting CAB+RPV in routine clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
Overton, E. T., Richmond, G., Rizzardini, G., Thalme, A., Girard, P.-M., Wong, A., Porteiro, N., Swindells, S., Reynes, J., Noe, S., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad020 · Cited by 145
Self-citationJaeger, H., Overton, E. T., Richmond, G., Rizzardini, G., Andrade-Villanueva, J. F., Mngqibisa, R., Hermida, A. O., Thalme, A., Belonosova, E., Ajana, F., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00185-5 · Cited by 142
Self-citation
Metadata
- Authors
- Cutrell, A. G., Schapiro, J. M., Perno, C. F., Kuritzkes, D. R., Quercia, R., Patel, P., Polli, J. W., Dorey, D., Wang, Y., Wu, S., Van Eygen, V., Crauwels, H., Ford, S. L., Baker, M., Talarico, C. L., Clair, M. S., Jeffrey, J., White, C. T., Vanveggel, S., Vandermeulen, K., Margolis, D. A., Aboud, M., Spreen, W. R., & van Lunzen, J.
- Venue
- AIDS
- Published
- 2021-04-09
- Volume
- 35
- Issue
- 9
- Pages
- 1333-1342
- ISSN
- 0269-9370 (ISSN-L)
- 1473-5571
- OpenAlex
- W3137565606
- Cited by
- 211
- References
- 1
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. https://app.cochat.ai/papers/10.1097/qad.0000000000002883
- The paper
- Cutrell, A. G., Schapiro, J. M., Perno, C. F., Kuritzkes, D. R., Quercia, R., Patel, P., Polli, J. W., Dorey, D., Wang, Y., Wu, S., Van Eygen, V., Crauwels, H., Ford, S. L., Baker, M., Talarico, C. L., Clair, M. S., Jeffrey, J., White, C. T., Vanveggel, S., . . . van Lunzen, J. (2021). Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. https://doi.org/10.1097/qad.0000000000002883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.